Every L&D content strategy is built on the same formula. The budget is divided by cost per asset; the result is set as the strategy. Exceed that result, and the additional amount will be carried forward for future consideration or discussed as part of next year’s budgeting process.
One big pharma company defied that math, not by much, but enough to matter. The plan was for 70 learning assets, though. Rather, they shipped 169 at a lower per-unit cost than projected in the original estimate. There were no more employees and no more budget; it was just another production model within the same engagement and scope with a different delivery.
Why Do Most L&D Content Strategies Become a Ceiling, Not a Target?
Most production schedules have an upper limit because output is measured in hours, and hours are costly. Then, layered in pharma-specific pressures, regulated review, multiple languages, 24/7 compliance demands, and a fixed-capacity team, the business’s year-end goals are just not something they can even pretend to meet. Anything above the annual figure becomes a backlog.
Pharma content is not like content in most other industries. Every asset undergoes technical, legal, and regulatory review before it is released. It has to exist in more than one language because the workforce training for it isn’t limited to a single country, and the demand never really pauses.
Aggregate numbers across the industry bear this out. The 2026 State of the Industry report from the Association for Talent Development (ATD) reports that average direct learning spending per employee decreased from $1,254 in 2024 to $846 in 2025, while formal learning hours per employee increased from 13.7 to 16.7. More learning is required, less budget to make it happen. That was the exact challenge this pharma company had to overcome.
With a stable team model, almost everything, including the asset, is built from scratch. SMEs are drawn into protracted cycles of extraction and review. Hours scale with output, dollar for dollar. So, a plan that says 70 assets is not really a target. There is a hard stop dictated by the number of individuals and the budget.
How Does a Studio-on-Demand Model Change L&D Production Capacity?
A studio-on-demand approach makes fixed capacity elastic. It right-sizes resourcing to what each asset really needs and isn’t, protects SME time above just about anything else, and allows AI to operate in a QC-gated process rather than bouncing around it.
Three decisions define the work. For one thing, the resources are scaled to the asset rather than to the contract. In a rigid system, all projects — simple or complex — draw from one resource pool, and the boring work ties up your best people while the challenging problems go unaddressed. A tiered system fixes that. Normal teams have routine builds; senior teams have complex builds; capacity is no longer a single, fixed bucket.
Second, SME time gets protected like the scarce resource it actually is. In pharma, the real bottleneck was never design hours; it’s getting an expert’s calendar. So, the model tackles that constraint head-on.
Existing documentation, SOPs, source material — all of it gets extracted to pull 70 to 80% of the content before an SME even enters the picture. Experts review and correct rather than build from a blank page. That alone takes expert availability out of the critical path.
Third, AI is integrated into a staged QA process (design, prototype, production, launch) rather than being used to skip it. That distinction is more important in a regulated environment than anywhere else. Speed without quality or accuracy is not a productivity win; it’s a compliance risk waiting to happen. And this is not a one-time move, either.
What Results Came from Breaking the Traditional Cost Model?
The numbers tell the story. The team delivered 169 assets against a plan of 70—that’s roughly 141% above target. And costs moved in the opposite direction, falling 36% through AI-assisted production. Output more than doubled while unit costs fell. That’s not how a linear model works under this kind of overrun.
In a traditional engagement, going over a plan by 140% means a change of order and a budget conversation that no one wants to have. Here, the engagement absorbed it because throughput was never tied to hours worked in the first place.
The plan stopped being a ceiling and started acting like a floor. That’s the inversion most organizations still haven’t managed to pull off, per ATD’s own numbers, which show budgets shrinking while demand for learning hours keeps climbing.
Does Higher Content Volume Mean Lower Quality?
Absolutely not, which is always the first objection that gets thrown out there; all 169 learning assets went through a four-step quality control process. On another project involving the same customer, multilingual delivery in 14 countries boosted completion rate by 18.3%. This was driven more by stronger instructional design than by a faster turnaround time.
Twice the output doesn’t necessarily mean twice the compromise in quality, and the results here definitely prove that. The regulated content still had to go through technical, legal, and regulatory checks at every stage, without exception.
Behind the scenes, the team refers to this as “factory with craftsmanship,” meaning the assembly line moves smoothly and predictably without devolving into cookie-cutter production. The increase in output was achieved through improved architecture, not by lowering quality standards.
What Should You Ask When Evaluating a Managed Learning Services (MLS) Provider?
Ask one question: What happened the last time a client’s actual demand blew past the contracted plan?
If the answer involves a change order and a cost card, that’s a linear model, and every asset past plan will cost you more, proportionally, forever. If the answer is an architecture that absorbs the remainder, that provider can actually scale alongside you rather than charging you for the privilege.
That single question tells you almost everything. In this case, the plan said 70, the business needed more, and the architecture delivered 169 at a lower cost than planned.
Are You Ready to Solve Your Own L&D Cost Curve?
This didn’t happen by luck. The pharma company followed a real maturity path, moving from scattered, ad hoc outsourcing toward a fully integrated, elastic MLS model. Most organizations are somewhere on that curve right now, often without a clear examination of exactly where they sit or what the next stage requires.
Our infographic, The MLS Maturity Curve, lays out the stages from a capped, linear content model to one built to absorb demand, as this one did. Worth a look if you want to see where your current setup stands.
Frequently Asked Questions (FAQs)
-
remove How do managed learning services help organizations scale learning content?Managed learning services provide access to flexible teams, production capabilities, technology, and established workflows. This allows organizations to increase or decrease learning production based on demand rather than relying entirely on permanent internal resources.
-
add How can pharmaceutical companies scale training content?Pharmaceutical companies can scale training content by combining standardized learning processes, specialized L&D expertise, technology-enabled production, and flexible capacity. This approach can help support large volumes of training while maintaining consistency across business and regulatory requirements.
-
add How much can organizations save with Managed Learning Services?Savings vary by organization, operating model, content volume, technology, and internal costs. Savings can come from production efficiencies, vendor consolidation, automation, standardized workflows, and more flexible resource utilization rather than from outsourcing alone.
-
add How do managed learning services improve L&D efficiency?MLS providers can improve L&D efficiency by centralizing workflows, standardizing production processes, reducing duplicated effort, automating repetitive activities, and providing specialized resources when needed. This enables internal L&D teams to focus more heavily on strategy and business priorities.
